Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04480086 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic considerations

Conditions

Myelofibrosis (MF)

Interventions

DRUG: Mivebresib
DRUG: Navitoclax
DRUG: Ruxolitinib

Sponsor

AbbVie